Michael D Gilman

US Patent:

6479653, Nov 12, 2002

Filed:

Jul 13, 2000

Appl. No.:

09/615917

Inventors:

Sridaran Natesan - Chestnut Hill MA
Michael Z. Gilman - Newton MA

Assignee:

ARIAD Gene Therapeutics, Inc. - Cambridge MA

International Classification:

C07H 2104

US Classification:

536 234, 4353201, 435325

Abstract:

The present invention relates to novel fusion proteins which activate transcription, to nucleic acid constructs encoding the proteins and their use in the genetic engineering of cells.

US Patent:

6506379, Jan 14, 2003

Filed:

Jan 12, 2000

Appl. No.:

09/481620

Inventors:

Timothy P. Clackson - Cambridge MA
Michael Gilman - Newton MA
Dennis Holt - Royersford PA

Assignee:

Ariad Gene Therapeutics, Inc. - Cambridge MA

International Classification:

A61K 4800

US Classification:

424 9321, 4353201

Abstract:

This invention concerns new configurations for biological switches and provides new methods and materials useful for regulating biological events in animal cells. The invention involves recombinant DNA constructs comprising DNA sequences derived from sequences encoding the proteins FRAP, Tor1, Tor2 and other proteins capable of binding to FKBP:rapamycin, other recombinant DNA constructs comprising DNA sequences encoding part or all of an FKBP protein, the proteins encoded by those constructs, cells (especially animal cells) transformed with one or more of the constructs, small molecules (multivalent multimerizing agents) which bind to and are capable of inducing multimerization of the chimeric proteins, and methods for preparing and using the foregoing, including methods involving the intramuscular delivery of such recombinant DNA constructs in AAV virus particles.

US Patent:

6649595, Nov 18, 2003

Filed:

Feb 12, 2001

Appl. No.:

09/781804

Inventors:

Timothy P. Clackson - Arlington MA
Michael Z. Gilman - Newton MA
Dennis A. Holt - Royersford PA
Terence P. Keenan - Cambridge MA
Leonard Rozamus - Bedford MA
Wu Yang - Princeton NJ

Assignee:

ARIAD Gene Therapeutics, Inc. - Cambridge MA

International Classification:

C12N 510

US Classification:

514 31, 435325, 435355, 435372, 4353723, 435375, 536 65

Abstract:

Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.

US Patent:

6693189, Feb 17, 2004

Filed:

Jul 10, 2001

Appl. No.:

09/902180

Inventors:

Dennis A. Holt - Stow MA
Terence P. Keenan - Cambridge MA
Timothy P. Clackson - Cambridge MA
Leonard Rozamus - Bedford MA
Wu Yang - Chestnut Hill MA
Michael Z. Gilman - Newton MA

Assignee:

Ariad Gene Therapeutics, Inc. - Cambridge MA

International Classification:

C07D48700

US Classification:

540456, 514183, 514291

Abstract:

This invention concerns derivatives of rapamycin and their antifungal uses. Also disclosed are materials and methods relevant to the identification of non-immunosuppressive anti-fungal rapamycin derivatives. Use of compounds, among others, of the formula is disclosed, where the various substitutents are as defined.

US Patent:

20030143731, Jul 31, 2003

Filed:

Oct 23, 2001

Appl. No.:

10/002244

Inventors:

Michael Gilman - Newton MA, US
Sridaran Natesan - Chestnut Hill MA, US

Assignee:

ARIAD Gene Therapeutics, Inc.

International Classification:

A61K048/00
C12N005/06
C12N015/87

US Classification:

435/325000, 435/320100, 435/455000, 514/044000

Abstract:

This invention provides novel materials and methods involving the heterologous expression of transcription factors which are useful for effecting transcription of target genes in genetically engineered cells or organisms containing them. Target gene constructs and other materials useful for practicing the invention are also disclosed.

US Patent:

20030206891, Nov 6, 2003

Filed:

Jan 14, 2003

Appl. No.:

10/341967

Inventors:

Timothy Clackson - Cambridge MA, US
Michael Gilman - Newton MA, US
Dennis Holt - Royersford PA, US

Assignee:

ARIAD Gene Therapeutics, Inc.

International Classification:

A01K067/027
A61K048/00
A61K031/4745
C12N005/08

US Classification:

424/093210, 800/014000, 514/044000, 514/291000, 435/366000

Abstract:

This invention concerns new configurations for biological switches and provides new methods and materials useful for regulating biological events in animal cells. The invention involves recombinant DNA constructs comprising DNA sequences derived from sequences encoding the proteins FRAP, Tor1, Tor2 and other proteins capable of binding to FKBP:rapamycin, other recombinant DNA constructs comprising DNA sequences encoding part or all of an FKBP protein, the proteins encoded by those constructs, cells (especially animal cells) transformed with one or more of the constructs, small molecules (multivalent multimerizing agents) which bind to and are capable of inducing multimerization of the chimeric proteins, and methods for preparing and using the foregoing, including methods involving the intramuscular delivery of such recombinant DNA constructs in AAV virus particles.

US Patent:

20040082515, Apr 29, 2004

Filed:

Nov 18, 2003

Appl. No.:

10/716062

Inventors:

Timothy Clackson - Arlington MA, US
Michael Gilman - Newton MA, US
Dennis Holt - Schwenksville PA, US
Terence Keenan - Cambridge MA, US
Leonard Rozamus - Bedford MA, US
Wu Yang - Princeton NJ, US

Assignee:

ARIAD Gene Therapeutics, Inc.

International Classification:

A61K039/395
G01N033/53

US Classification:

514/012000, 424/130100

Abstract:

Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.

US Patent:

20040265288, Dec 30, 2004

Filed:

Jul 16, 2004

Appl. No.:

10/893199

Inventors:

Michael Gilman - Newton MA, US

International Classification:

A61K048/00
C12N005/08

US Classification:

424/093210, 514/044000, 435/366000

Abstract:

This invention provides new applications of regulated gene therapy relating to treatment of cancer and other disorders.